adeno-associated virus-based SMN1 gene therapy (Pfizer/University of Navarra)

N/A

Report date: 2025/06/11 11:07:23

Base Information

Drug Nameadeno-associated virus-based SMN1 gene therapy (Pfizer/University of Navarra)
Drug Alias NameAAV9PHP.B-CBh-SMN1SMN1 gene therapy (Pfizer/University of Navarra)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSurvival motor neuron protein stimulants
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Navarra
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncUniversity Of Navarra
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A